热门资讯> 正文
吉姆·克莱默（Jim Cramer）发表评论后，库拉肿瘤学（Kura Oncology）上涨
2025-12-23 01:01
- A mention on the Dec. 19 episode of CNBC's "Mad Money" hosted by Jim Cramer of Kura Oncology (KURA) is sending shares of the biotech higher by 12% in Monday trading.
- Cramer said, "I have always felt that if you have something that is for cancer and it works, then you have to own the stock as a speculation, but just as a speculation, because it’s been such a difficult disease."
- He was referring to Komzifti (ziftomenib), which just gained US FDA approval in November for acute myeloid leukemia. The drug is marketed with Japanese drugmaker Kyowa Kirin (KYKOF) (KYKOY).
- Approval triggered a $135M milestone payment from Kyowa Kirin to Kura.
More on Kura Oncology
- Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML - Slideshow
- Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
- Kura Oncology: A Cautious Buy
- Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
- Kura Oncology wins FDA approval for leukemia drug
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
